SCLC

[Nature Communications] To identify predictors of clinical benefit to immune checkpoint blockade, investigators performed immunogenomic profiling of tumor samples from patients with relapsed small cell lung cancer.

[Cancer Discovery] Scientists identified genomic contexts in which neuroendocrine transformation was favored, including frequent loss of the 3p chromosome arm.

[Translational Oncology] Experiments in a mouse xenograft model using allo lymphocytes showed that PTPN3 inhibition in small cell lung cancer cells enhanced the anti-tumor effect of phosphatase non-receptor type 3 (PTPN3)-suppressed activated lymphocytes.

[Cell Death & Disease] By performing whole-exome sequencing of 48 Small-cell carcinoma of the esophagus (SCCE) and 64 small-cell lung cancer (SCLC) tumor samples, respectively reserachers have shown that the number of driver mutations in SCCE was significantly lower than in SCLC

[Cancer Cell] Using chemical genetic screens, scientists identified inhibition of ataxia telangiectasia and rad3 related (ATR), the primary activator of the replication stress response, and topoisomerase I (TOP1), nuclear enzyme that suppressed genomic instability, as synergistically cytotoxic in small cell lung cancer (SCLC).

[Nature Communications] Scientists identified non-neuroendocrine SCLC to be vulnerable to ferroptosis through subtype-specific lipidome remodeling.